September 28, 2018 KSQ Therapeutics Secures $80 Million Financing and Advances Broad Pipeline of Cancer Therapies Including Its First Adoptive T-Cell Therapy Program for PD 1 Resistant Solid Tumors
September 25, 2018 KSQ Therapeutics Appoints Richard Moscicki, MD, to Board of Directors
October 02, 2017 KSQ Therapeutics Emerges with $76 Million in Financing to Pioneer High-Confidence Drug Development
